Skip to main content

Advertisement

SpringerLink
Log in

Infliximab can induce a prolonged clinical remission and a decrease in thyroid hormonal requirements in a patient with SAPHO syndrome and hypothyroidism

  • Case Report
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

SAPHO syndrome is a rare entity that compromises the skeletal system (arthritis–osteitis) and is associated with various dermatological conditions such as palmoplantaris pustulosis (PPP) and acne. We present the case of a 39-year-old man with invalidating arthritis derived from a SAPHO syndrome and hypothyroidism (after radioiodine treatment for a Graves’ disease). Due to the severity and refractoriness of his disease, we decided to use infliximab. He showed a prompt and prolonged response of his joint and cutaneous manifestations after three doses of a tumor necrosis factor alpha (TNF-α) blocker. Interestingly, he also decreased his levothyroxine requirements after TNF-α blockade therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hayem G, Bouchaaud-Cahbot A, Benali K et al (1999) SAPHO syndrome: a longterm follow-up study of 120 cases. Semin Arthritis Rheum 29:159–171

    Article  PubMed  CAS  Google Scholar 

  2. Wagner AD, Andresen J, Jendro MC et al (2002) Sustained response to tumor necrosis factor alpha-blocking agents in two patients with SAPHO syndrome. Arthritis Rheum 46:1965–1968

    Article  PubMed  Google Scholar 

  3. Iqbal M, Kolodney M (2005) Acne fulminans with synovitis–acne–pustulosis–hyperostosis–osteitis (SAPHO) syndrome treated with infliximab. J Am Acad Dermatol 52(Suppl 1):S118–120

    Article  PubMed  Google Scholar 

  4. Olivieri I, Padula A, Ciancio G et al (2003) Persistent efficacy of tumor necrosis factor alpha blockage therapy in SAPHO syndrome: comment on the article by Wagner et al. Arthritis Rheum 48:1467–1468

    Article  PubMed  Google Scholar 

  5. Olivieri I, Padula A, Ciancio G et al (2002) Successful treatment of SAPHO syndrome with infliximab: report of two cases. Ann Rheum Dis 61:375–376

    Article  PubMed  CAS  Google Scholar 

  6. Massara A, Cavazzini PL, Trotta F (2006) In SAPHO syndrome anti-TNF-therapy may induce persistent amelioration of osteoarticular complaints, but may exacerbate cutaneous manifestations. Rheumatology 45:730–733

    Article  PubMed  CAS  Google Scholar 

  7. Roux CH, Brocq O, Leccia N et al (2007) New-onset psoriatic palmoplantaris pustulosis following infliximab therapy: a class effect? J Rheumatol 34:434–437

    PubMed  Google Scholar 

  8. Dutz JP (2007) Tumor necrosis factor-α inhibition and palmoplantar pustulosis: Janus-faced therapy? J Rheumatol 34:247–249

    PubMed  CAS  Google Scholar 

  9. Alvaro-Gracia JM, Yu C, Zvaifler NJ et al (1993) Mutual antagonism between interferon-gamma and tumor necrosis factor-alpha on fibroblast-like synoviocytes: paradoxical induction of IFN-gamma and TNF-alpha receptor expression. J Clin Immunol 13:212–218

    Article  PubMed  CAS  Google Scholar 

  10. Pang XP, Hershman JM, Chung M et al (1989) Characterization of tumor necrosis factor-alpha receptors in human and rat thyroid cells and regulation of the receptors by thyrotropin. Endocrinology 125:1783–1788

    Article  PubMed  CAS  Google Scholar 

  11. Bartalena L, Bogazzi F, Brogioni S et al (1998) Role of cytokines in the pathogenesis of the euthyroid sick syndrome. Eur J Endocrinol 138:603–614

    Article  PubMed  CAS  Google Scholar 

  12. Tang KT, Braverman LE, DeVito WJ (1995) Tumor necrosis factor-alpha and interferon-gamma modulate gene expression of type I 5′-deiodinase, thyroid peroxidase, and thyroglobulin in FRTL-5 rat thyroid cells. Endocrinology 136:881–888

    Article  PubMed  CAS  Google Scholar 

  13. Diez JJ, Hernanz A, Medina S et al (2002) Serum concentrations of tumour necrosis factor-alpha (TNF-alpha) and soluble TNF-alpha receptor p55 in patients with hypothyroidism and hyperthyroidism before and after normalization of thyroid function. Clin Endocrinol Oxford 57:515–521

    Article  CAS  Google Scholar 

  14. Miyakoshi H, Ohsawa K, Yokoyama H et al (1992) Exacerbation of hypothyroidism following tumor necrosis factor-alpha infusion. Intern Med 31:200–203

    Article  PubMed  CAS  Google Scholar 

  15. Jones BM, Kwok CC, Kung AW (1999) Effect of radioactive iodine therapy on cytokine production in Graves′ disease: transient increases in interleukin-4 (IL-4), IL-6, IL-10, and tumor necrosis factor-alpha, with longer term increases in interferon-gamma production. J Clin Endocrinol Metab 84:4106–4110

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Rheumatology Section, Department of Medicine, Clinical Hospital, University of Chile, Santos Dumont N°999, Independencia, Santiago, Chile

    Francisca Sabugo, Lilian Soto & Miguel Cuchacovich

  2. Endocrinology Section, Department of Medicine, Clinical Hospital, University of Chile, Santiago, Chile

    Claudio Liberman

  3. Department of Radiology, Alemana Clinic, Santiago, Chile

    Juan Pablo Niedmann

  4. Rheumatology Section, Department of Medicine, Las Condes Clinic, San Pio X, No. 2460 Off 607, Providencia, Santiago, Chile

    Miguel Cuchacovich

Authors
  1. Francisca Sabugo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Claudio Liberman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Juan Pablo Niedmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lilian Soto
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Miguel Cuchacovich
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Miguel Cuchacovich.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sabugo, F., Liberman, C., Niedmann, J.P. et al. Infliximab can induce a prolonged clinical remission and a decrease in thyroid hormonal requirements in a patient with SAPHO syndrome and hypothyroidism. Clin Rheumatol 27, 533–535 (2008). https://doi.org/10.1007/s10067-007-0767-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-007-0767-y

Keywords

Search

Navigation